StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)

Close on Nov 13, 2026Market cap $153.37MP/E –Yield –

Earnings

Fate Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
– on a year earlier
EPS, Q3 FY2026
-$0.25
Latest guidance
Issued
May 3, 2023 · 3 items

Quarterly results

Revenue and earnings per share from each of Fate Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open––-$0.25Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open$2.10M+10.5%-$0.25Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open$1.30M-18.8%-$0.26Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$1.40M-26.3%–Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open$1.70M-45.2%–Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025during market hours$1.90M-72.1%-$0.29Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours$1.60M-15.8%–Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025during market hours$1.90M+11.8%-$0.44Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours$3.10M+63.2%-$0.40Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024during market hours$6.80M+655.6%-$0.33Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours$1.90M-96.8%-$0.47Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Fate Therapeutics guided for has been reported

Guidance history

Every forecast Fate Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 3, 2023cash, cash equivalents, and investmentsFY2023$300.00MNew
May 3, 2023GAAP operating expensesFY2023$265.00M – $285.00MNew
May 3, 2023revenue under the ONO collaborationFY2023$800.00KNew
Feb 28, 2022GAAP Loss from OperationsFY2022$335.00M – $365.00MNew
Feb 28, 2022cash useFY2022$290.00M – $315.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Fate Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
    Results
  2. Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
    News
  3. Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
    Results
  4. TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies
    News
  5. Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
    Results
  6. Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
    Results
  7. Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
    Results
  8. Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with
    Update
  9. Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
    Update
  10. Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
    Results
  11. Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
    Update
  12. Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
    Results
  13. Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
    Results
  14. Fate Therapeutics Announces Leadership Transition
    Update
  15. Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
    Results

See a number that looks wrong?